Expert Perspectives: Optimizing Dosing Strategy for Late-Line Therapies in mCRC

Expert Perspectives: Optimizing Dosing Strategy for Late-Line Therapies in mCRC

On-Demand Webcast

Axel Grothey, MD
Mayo Clinic
Scottsdale, Arizona


Tanios S. Bekaii-Saab, MD
Mayo Clinic
Scottsdale, Arizona

Eric Van Cutsem, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Target Audience

This online educational activity is designed to meet the educational needs of global oncologists (primary: medical oncologists; secondary: radiation oncologists, surgical oncologists), as well as other healthcare professionals who care for patients with CRC, including oncology fellows, oncology nurses, and pharmacists.


As the standard of care and novel strategies for the management of refractory colorectal cancer (CRC) are further investigated and refined, it is essential that healthcare professionals who care for these patients are provided with guidance for the successful integration of these potentially paradigm-changing advances into their clinical practice. To this end, this activity has been designed to inform oncologists who manage patients with metastatic CRC how to safely and effectively incorporate dose optimization strategies and sequencing into current clinical algorithms. This online roundtable discussion provides the perspectives of renowned clinical experts, Drs. Axel Grothey, Eric Van Cutsem, and Tanios S. Bekaii-Saab, on the latest advances and insights from pivotal clinical trials.


Upon successful completion of this educational activity, participants should be better able to:

  1. Assess the therapeutic management of refractory mCRC, including emerging approaches to reduce treatment-related toxicity, prolong survival, and enhance quality of life (QOL)
  2. Devise dose optimization strategies for managing treatment-related adverse events for patients with refractory mCRC
  3. Analyze data from recent clinical trials on novel dosing and sequencing strategies that mitigate adverse events, prolong survival, and enhance QOL for patients with refractory mCRC
  4. Assess evidence-based algorithms for sequencing of late-line mCRC therapies

This activity is provided by Imedex®, LLC.

Continuing Education


Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this internet-based enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hour of Category 1 credit for completing this program.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.


Supported by an educational grant from: Bayer HealthCare Pharmaceuticals, Inc.


As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options by utilizing generic names to ensure impartiality.

All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

Tanios Bekaii-Saab, MD Armo2; Exelixis2; Merck2; SillaJen2
Eric Van Cutsem, MD, PhD Amgen1; Bayer HealthCare Pharaceuticals, Inc.1,2; Boeringer Ingelheim1; Celgene1,2; Ipsen1; Lilly1,2; Merck Sharp & Dohme Corp.1; Merck1; Novartis1,2; Roche1; Servier1,2

The following speakers do not report any affiliation:

Axel Grothey, MD  

All materials are included with the permission of the authors.

Imedex, LLC Staff Disclosure of Financial Relationships
All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

   Chris Bolwell owns shares of stock of GlaxoSmithKline.

Unapproved Uses

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

© 2018 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

For comments or inquiries, please contact:
Imedex, LLC
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Fax: +1(770) 751-7334

Release Date: March 30, 2018

Expiration Date: March 30, 2019